TABLE 1.
Summary of phase I HIV vaccine trials used for comparison
| Trial no. | Source (reference) | Strategy | Vector or boost | Immunogen(s) | Adjuvant | Immunization times (wk) |
|---|---|---|---|---|---|---|
| RV138 | Eller et al. (21) | Canarypox virus vector | ALVAC-HIV (vCP205) | Env/Gag/Pro—autologous DC, i.d., i.m. | 0, 4, 12, 24 | |
| RV172 | Kibuuka et al. (35) | DNA prime, Ad5 boost | Multiclade DNA | Gag/Pol/Nef/Env | 0, 4, 8 | |
| rAd5 | Matching proteins (except Nef) | 24 | ||||
| RV114 | Pitisuttithum et al. (36) | Protein | Protein | rgp120 (SF2) | MF59 | 0, 4, 16 |
| RV132 | Thongcharoen et al. (24) | Canarypox virus vector prime, canarypox virus vector/protein boost | ALVAC-HIV (vCP1521) | 92TH023 gp120-LAI gp41 + LAI Gag/protein | 0, 4, 12, 24 | |
| Protein (oligomeric gp160) | 92TH023 gp120-LAI gp41 + LAI Gag/protein | PCPP | 12, 24 | |||
| Protein (bivalent gp120) | CM235 (100 μg) + SF2 (50 μg) | MF59 | 12, 24 | |||
| RV135 | Nitayaphan et al. (25) | Canarypox virus vector prime, canarypox virus vector/protein boost | ALVAC-HIV (vCP1521) | 92TH023 gp120-LAI gp41 + LAI Gag/protein | 0, 4, 12, 24 | |
| AIDSVAX (B/E) | MN (B) and A244 (E) gp120 | Alum | 12, 24 | |||
| RV158 | Currier et al. (22) | Cowpox virus vector | MVA-CDMR | gp160 (CM235, E), Gag/Pol (CM240, A) | 0, 4, 12 | |
| RV144 | Rerks-Ngarm et al. (4) | Canarypox virus vector prime, canarypox virus vector/protein boost | ALVAC-HIV (vCP1521) | 92TH023 gp120-LAI gp41 + LAI Gag/protein | 0, 4, 12, 24 | |
| Bivalent protein (AIDSVAX [B/E]) | MN (B) and A244 (E) gp120 | Alum | 12, 24 |